CoChat

Neonatal Abstinence Syndrome After Methadone or Buprenorphine Exposure

Jones, Hendrée E., Kaltenbach, Karol, Heil, Sarah H., Stine, Susan M., Coyle, Mara G., Arria, Amelia M., O'Grady, Kevin E., Selby, Peter, Martin, Peter R., Fischer, Gabriele · 2011 · Obstetrical & Gynecological Survey
Cited by 112

The DOI matches its Crossref record.

Abstract

The recommended treatment for opioid dependence in pregnant women is methadone, a full mu-opioid agonist. However, in utero exposure to methadone is associated with neonatal abstinence syndrome (NAS) that is characterized by hyperirritability of the central nervous system and a dysfunctional autonomic nervous system. Management of NAS often requires prolonged hospitalization and pharmacologic intervention. A partial mu-opioid agonist, buprenorphine, has been investigated as an alternative treatment for opioid dependence but relatively few studies of this drug have been conducted in pregnant women. Some prospective open-label and controlled studies suggest that NAS occurring in neonates treated prenatally with buprenorphine was less likely to require treatment than NAS in neonates exposed to prenatal methadone. However, the results of these studies have been inconsistent. This double-blind, randomized, controlled study compared the use of buprenorphine and methadone for management of pregnant women with opioid dependency. The study subjects were 175 pregnant opioid-dependent women enrolled at 8 international sites. A total of 131 of these women completed the trial; 58 (44%) were patients receiving buprenorphine and 73 (56%) were women treated with methadone. The 5 primary neonatal outcomes included the number of neonates requiring treatment for NAS, the peak NAS score, the total amount of morphine needed to treat NAS, length of hospital stay, and head circumference. The P values for all group comparisons were calculated according to prespecified thresholds for significance. More women receiving prenatal buprenorphine (28/86, 33%) discontinued treatment as compared with those receiving prenatal methadone (16/89, 18%). In comparison with methadone, neonates of women treated with prenatal buprenorphine required significantly less morphine (mean dose, 1.1 vs. 10.4 mg; P < 0.009), had a 43% decrease in the hospital stay (10.0 vs. 17.5 days, P < 0.009), and spent 58% less time in the hospital receiving medication for NAS (4.1 vs. 9.9 days, P < 0.003). No significant differences were found between groups for other primary or secondary outcomes, including the number of neonates requiring NAS treatment, the peak NAS score, head circumference, or any other adverse neonatal or maternal outcome. These findings suggest that buprenorphine is an acceptable alternative to methadone for treatment for opioid dependency during pregnancy and with further studies, may actually be the preferred therapeutic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ogx.0b013e318225c419

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 112

Metadata

Authors
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G.
Venue
Obstetrical & Gynecological Survey
Published
2011-04
Volume
66
Issue
4
Pages
191-193
ISSN
0029-7828 (ISSN-L)
OpenAlex
W2333015707
Cited by
112
References
0
FWCI
21.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neonatal Abstinence Syndrome After Methadone or Buprenorphine Exposure. https://app.cochat.ai/papers/10.1097/ogx.0b013e318225c419
The paper
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2011). Neonatal Abstinence Syndrome After Methadone or Buprenorphine Exposure. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0b013e318225c419

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.